Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1

Project: Other project

Project Details

StatusActive
Effective start/end date3/10/20 → 2/28/25

Funding

  • National Inst of Allergy & Infectious Di: $1,023,759.75